• MK-8745: Aurora A Inhibitor Assay Workflows

  2026-08-30

  MK-8745 converts Aurora A biology into practical assays for mitotic arrest, tetraploidy, and apoptosis. This workflow connects high-risk retinoblastoma findings with carefully controlled cell-based, lymphoma, and xenograft experiments.

• ZDHHC4 Palmitoylation and TRPV1 Pain Relief

  2026-08-29

  A 2025 EMBO Reports study identifies ZDHHC4-mediated S-palmitoylation as a mechanism that reduces TRPV1 activity during inflammatory pain relief by promoting lysosomal degradation of the channel. The work also positions APT1-dependent depalmitoylation as a counter-regulatory process that can restore nociceptive signaling.

• Berbamine Hydrochloride and Ferroptosis Strategy

  2026-08-28

  Berbamine hydrochloride offers a mechanistically rich research entry point for connecting STAT3, calcium homeostasis, NF-κB activity, and ferroptosis-resistance biology. This translational framework uses the METTL16-SENP3-LTF axis in hepatocellular carcinoma to define testable hypotheses while separating established product data from future experimental validation.

• D-N-Acetylgalactosamine: Protocol and QC Guide

  2026-08-28

  D-N-Acetylgalactosamine (SKU B7904) provides a defined, water-compatible amino sugar for workflows examining glycoprotein composition, brain heteropolysaccharides, and related glycosylation pathways. It is appropriate for aqueous or validated DMSO-based procedures, but should not be selected for ethanol-based systems or long-term storage of prepared solutions.

• FerroOrange and the Translational Iron Signal

  2026-08-27

  A mechanistic and strategic guide to using FerroOrange, a live-cell Fe²⁺ fluorescent probe, to connect intracellular iron detection with ferroptosis, macrophage biology, and translational research.

• 2X Taq PCR Master Mix (with dye): Assay QC

  2026-08-27

  A scenario-driven guide to using 2X Taq PCR Master Mix (with dye), SKU K1034, as an orthogonal molecular quality-control tool alongside cell viability, proliferation, and cytotoxicity assays. It explains assay compatibility, endpoint-PCR interpretation, protocol setup, TA cloning, and practical vendor-selection criteria.

• miR-18a, ALOXE3, and Glioblastoma Ferroptosis

  2026-08-26

  The reference study identifies a miR-18a–ALOXE3 axis that links lipid metabolism, ferroptosis resistance, and migration in glioblastoma. Its findings position ALOXE3-mediated lipid signaling as a mechanistic framework for studying tumor growth and provide a basis for evaluating p53-linked interventions without equating them to validated GBM therapies.

• EVMPs Enable Extrahepatic IL-12 mRNA Delivery

  2026-08-26

  The reference study presents a self-assembling enveloped virus-mimicking particle (EVMP) designed to overcome the hepatic bias of many conventional mRNA carriers. By combining an engineered virus-mimicking peptide with selected phospholipids, the authors achieved lung- and spleen-directed delivery and used IL-12 mRNA to suppress metastatic lung tumor progression.

• Naloxone Hydrochloride: Research Workflows

  2026-08-25

  Use naloxone hydrochloride to separate opioid receptor-dependent effects from withdrawal, behavioral, cellular, and immune outcomes. This practical guide connects antagonist challenge designs with neural stem cell assays and troubleshooting strategies for reproducible opioid research.

• Biomimetic Nanoparticles for Inflammatory DOR

  2026-08-25

  The reference study developed PLGA@AC@FSHL-M nanoparticles to deliver α-cyperone to LPS-stressed KGN granulosa cells through a macrophage-membrane and FSHL81-95 peptide design. The nanocomplex reduced inflammatory cytokines and ROS while activating Nrf2/HO-1 and suppressing NF-κB, providing an important cell-model rationale for targeted antioxidant strategies in diminished ovarian reserve research.

• Calpain Inhibitor II, ALLM: Assay Logic

  2026-08-24

  Calpain Inhibitor II, ALLM provides a cell-permeable way to interrogate calpain and cathepsin-dependent proteolysis. This guide connects the FAISL–calpain 2–FAK mechanism in breast cancer with practical assay designs that separate protease activity from apoptosis.

• Tubastatin A: From HDAC6 to Cell-Death Assays

  2026-08-24

  Tubastatin A is a selective HDAC6 inhibitor with a distinctive post-resuscitation myocardial protection profile. This article translates porcine cardiac-arrest findings into practical assay and experimental-design decisions while defining what the evidence does—and does not—establish.

• MLN2238: Practical Proteasome β5 Inhibition

  2026-08-23

  MLN2238 is a reversible 20S proteasome probe built around potent β5-site inhibition, making it useful for apoptosis, resistance, and proteotoxic-stress workflows. This guide connects concentration-controlled oncology assays with the CRTC-CREB stress-response findings reported in Drosophila and mammalian cells.

• ICOS–Th2 Signaling in Allergic Rhinitis

  2026-08-22

  The reference study links inducible co-stimulator (ICOS) signaling to T-cell imbalance in allergic rhinitis, with particular emphasis on Th2 differentiation and symptom severity. Its combination of immune profiling, longitudinal subcutaneous immunotherapy follow-up, and pathway inhibition provides a useful framework for evaluating ICOS-expressing Th2 cells as biomarkers and therapeutic targets.

• BRCAness and Olaparib Sensitivity in Mesothelioma

  2026-08-22

  Borchert et al. connected homologous recombination repair gene-expression patterns with olaparib response in malignant pleural mesothelioma models. Their results support BRCAness-based stratification, particularly in BAP1-altered tumors, while emphasizing that the proposed olaparib–cisplatin strategy remains an in vitro, hypothesis-generating approach.

8013 records 1/535 page Next 12345 下5页 Last page